Trial Profile

A Study Evaluated Efficacy and Safety of CD19/22 Chimeric Antigen Receptor T Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Anti CD22 chimeric antigen receptor T cell therapy-Shanghai Unicar-Therapy Bio-medicine Technology (Primary) ; Anti-CD19 chimeric antigen receptor T cell therapy Shanghai Unicar Therapy Bio-medicine Technology (Primary) ; Tislelizumab (Primary)
Indications B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Therapeutic Use

01 Jan 2024 Results assessing whether CD19/22 CAR-T cell combined with tislelizumab elicit a safe and durable response in R/R B-NHL and may improve the prognosis of those patients, published in the Hematological Oncology
14 Dec 2021 Status changed from recruiting to active, no longer recruiting, according to results presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com